HCPCS code J0641 – Levoleucovorin injection

Key takeaways

HCPCS code J0641 covers injection, levoleucovorin, not otherwise specified, at 0.5 mg per unit, for Fusilev and generic levoleucovorin.

Khapzory bills under its own code, J0642, and racemic leucovorin calcium bills under J0640.

Unit calculation is a frequent error source, because a 200 mg dose equals 400 units of J0641.

NDC reporting is required by Medicaid and many commercial payers, so check each payer before you submit.

Pabau, the practice software we build, scrubs drug claims for missing or invalid details and carries prior authorization codes through to the claim.

HCPCS code J0641: Official descriptor and quick reference

HCPCS code J0641 is the code for injection, levoleucovorin, not otherwise specified, 0.5 mg. Each billable unit equals 0.5 mg of levoleucovorin given by injection. The code covers Fusilev and generic levoleucovorin products. Khapzory has its own code, J0642, so it never bills under J0641.

What J0641 covers and excludes

J0641 covers injectable levoleucovorin in two clinical roles. The first is rescue after high-dose methotrexate, including treatment of methotrexate toxicity. The second is combination therapy with fluorouracil in metastatic colorectal cancer, such as the FOLFOX and FOLFIRI regimens. These are the FDA-approved indications for Fusilev and its generic equivalents.

The following are excluded from J0641:

• Khapzory: This levoleucovorin product has its own code, J0642 (“Injection, levoleucovorin (khapzory), 0.5 mg”). Billing it under J0641 is a coding error.
• Oral levoleucovorin: Oral formulations are not injectable and do not map to J0641. Bill under a pharmacy drug code where applicable.
• Leucovorin calcium (racemic mixture): Maps to J0640, not J0641. Using J0641 for leucovorin is a coding error that generates denials.
• Compounded levoleucovorin: Compounded preparations are not covered under J0641 unless a payer-specific policy explicitly includes them. Verify before billing.
• Off-label indications: Claims for off-label use carry significant denial and audit risk. Medical necessity documentation must demonstrate the FDA-approved indication when billing J0641.

J0641 vs J0640: Levoleucovorin vs leucovorin billing

Levoleucovorin bills under J0641 and racemic leucovorin under J0640, and the two codes are not interchangeable. Levoleucovorin is the pharmacologically active L-isomer. Leucovorin is the racemic mixture of the L and D isomers. They are distinct drugs with different dosing conventions, different ASP-based payment rates, and different payer coverage policies.

The unit difference is the most common billing error. J0640 bills at 50 mg per unit, while J0641 bills at 0.5 mg per unit.

Swap the code on a 100-unit J0640 claim without recalculating, and the quantity is wrong by a factor of 100. Payers catch this with a claim edit and deny the whole line. Here is the same 200 mg dose under each code:

How to calculate and report billing units for J0641

J0641 billing units are calculated by dividing the dose administered in milligrams by 0.5 mg. Each unit equals 0.5 mg of levoleucovorin. For a 200 mg infusion, the unit count is 400. For a 100 mg dose, it is 200 units.

Drug wastage: Medicare pays for the discarded portion of a single-dose vial. The record must show the amount drawn, the amount given, and the amount wasted. Under the CMS Medicare Claims Processing Manual, Chapter 17, §40, the claim reports both the administered units and the wasted units. The wasted units go on their own line with the JW modifier.

When none of a single-dose vial is wasted, add the JZ modifier to the administered line instead. CMS has required JZ on those claims since July 2023. Check commercial payers separately, since many exclude wastage billing by contract.

NDC reporting requirements for HCPCS code J0641

National Drug Code (NDC) reporting on J0641 is required by Medicaid and many commercial payers, so check each payer’s rules. Medicare Part B does not generally require an NDC on J-code claims. A payer that does require one will deny a claim that arrives without it.

When submitting on a CMS-1500 paper claim or 837P electronic transaction, report the NDC in the following format:

• Qualifier: N4 (identifies the number as an NDC)
• NDC number: 11-digit format (5-4-2 digits, no hyphens in electronic claims)
• Unit qualifier: UN (units)
• Quantity: The number of units dispensed from the vial (not the billed units)

Each labeler assigns the NDCs for Fusilev and generic levoleucovorin, and they change with packaging updates. Always verify current NDCs against the FDA’s DailyMed database before submitting a claim. Never hardcode NDC numbers into billing templates. A stale NDC triggers a denial at any payer that checks it, and the appeal can take weeks.

ICD-10 diagnosis codes to pair with J0641

An unsupported or missing diagnosis code is a leading cause of J0641 claim denial. The ICD-10-CM codes below represent the most common medical necessity pairings for levoleucovorin injection. Verify each code against the current CMS ICD-10-CM tabular list before submission, as code structures change annually.

Payer local coverage determinations (LCDs) may specify a narrower list of acceptable diagnosis codes. Check the applicable LCD on the CMS HCPCS coding and billing resource page and your payer’s coverage policy. Do it before submitting claims with less common pairings such as E53.8.

Medicare reimbursement and ASP pricing for J0641

Medicare Part B reimburses J0641 at Average Sales Price (ASP) plus 6% in non-OPPS settings, such as a physician office. Hospital outpatient departments billing under OPPS receive a different payment rate based on the applicable Ambulatory Payment Classification (APC). The ASP+6% rate changes every quarter when CMS releases updated ASP pricing files.

Why no dollar figure is published here: ASP-based rates for J0641 change with each quarterly CMS update. Hardcoding a payment figure into billing documentation or system templates is a compliance risk, because teams keep billing the old rate after it changes.

Always retrieve the current quarter’s rate from the CMS Physician Fee Schedule search tool or the quarterly ASP drug pricing file published at cms.gov.

Prior authorization and step therapy requirements for J0641

Prior authorization requirements for J0641 vary by payer and plan year. Medicare fee-for-service (traditional Medicare) does not require prior authorization for J0641, but Medicare Advantage plans and commercial payers frequently do. Some payers also impose step therapy: The patient must have failed or been documented as intolerant of leucovorin (J0640) before J0641 will be authorized.

Step therapy is not a universal requirement. Patients with documented intolerance to leucovorin, or clinical scenarios where leucovorin is contraindicated, may qualify for a step-therapy exception. The documentation to support an exception typically includes:

• Physician attestation of leucovorin intolerance or contraindication
• Prior treatment records showing failed leucovorin therapy (where applicable)
• Clinical rationale for levoleucovorin as the medically necessary choice
• Diagnosis documentation confirming an FDA-approved indication

Always verify prior authorization requirements directly with the specific payer and plan before the date of service. Requirements change with plan year updates. A J0641 claim submitted without a required authorization is denied on first pass, and an appeal is the only way back. Tracking prior authorization status alongside medical billing compliance workflows reduces this exposure significantly.

Common claim denial reasons for HCPCS code J0641

J0641 denials follow predictable patterns. Most trace back to four root causes: Missing NDC, wrong units, unsupported diagnosis, and missing prior authorization. The table below maps each denial type to its resolution action. The reason codes on the remittance tell you which row applies, and our guide to medical billing denial codes explains each one.

Structured denial management processes catch these patterns before they pile up. Route J0641 denials into their own oncology drug workflow, separate from general claim denials. Resolution cycles shorten because each denial type has a fixed resolution path.

Documentation requirements for J0641 claims

Complete documentation in the medical record is what separates a payable J0641 claim from one that gets pulled in a post-payment audit. Every element below should be present in the record and consistent with what appears on the claim.

• Physician order: Written order specifying levoleucovorin by name, dose in mg, route, and frequency
• Diagnosis: ICD-10-CM code supported by clinical documentation (pathology report, chemotherapy protocol, or MTX toxicity labs)
• Drug identity: Brand name and NDC of the product administered (Fusilev or a generic levoleucovorin)
• Dose administered: Exact mg administered, confirmed against the physician order
• Route and date: IV infusion or IV push; date of administration matching claim date of service
• Units billed: Calculation documented (dose ÷ 0.5 = units billed)
• Wastage (if applicable): Volume drawn from vial, volume administered, volume wasted, reason for wastage
• Prior authorization number: Required by any payer that mandated PA; must appear on the claim
• Administration CPT code: Infusion or injection administration code billed alongside J0641 (see section below)

Consistent clean claim submission practices mean the documentation is complete before the claim is generated, not assembled after a denial. A pre-submission checklist in the clinical workflow reduces audit exposure for high-dollar oncology drug codes like J0641. A well-prepared superbill that captures NDC, units, and diagnosis at the point of service is the most reliable starting point.

Administration CPT codes to bill alongside J0641

J0641 is a drug code only, so it does not include the administration service. Bill a separate CPT administration code for the infusion or injection on the same date of service. Levoleucovorin is a rescue and modulating agent, not chemotherapy, so the default is the therapeutic infusion code 96365.

NCCI (National Correct Coding Initiative) edits govern bundling between J0641 and administration codes, so confirm current edits before billing both.

When levoleucovorin is infused as part of a multi-drug chemotherapy session, sequence the administration codes by the infusion hierarchy rules. The primary (highest-level) infusion is reported first, then add-on codes for drugs given in sequence or at the same time.

Check current NCCI edits through the AAPC HCPCS code lookup to see whether a J0641 and administration pair is bundled in your billing setting.

How Pabau keeps J0641 drug claims clean before they reach the payer

Most oncology billing teams check J0641 claims by hand. Someone converts the dose to units, looks up the NDC, and confirms the prior authorization number before the claim goes out. A missed step shows up weeks later as a denial.

Pabau moves those checks into the claim itself. Its infusion practice claims software scrubs every claim for missing or invalid details before it leaves Pabau. US claims then go out as CMS-1500s through Claim.MD to thousands of payers.

Prior authorizations are stored as cases, so the authorization code follows the appointment through to the claim. Any claim still missing a code gets flagged before submission. Your team fixes one field and resubmits, instead of building an appeal weeks later.

Send J0641 claims that pass the first time

Pabau checks each claim for missing or invalid details before it goes to the payer. Prior authorization codes follow the appointment through to the claim, so fewer drug lines come back denied.

Book a demo

Conclusion

J0641 claims fail on arithmetic and paperwork far more often than on clinical grounds. Bill units at 0.5 mg each, and confirm the product is Fusilev or a generic rather than Khapzory. Then check each payer’s NDC and wastage rules before the claim goes out.

The trade-off is a few minutes at the front of the process. A pre-submission check takes minutes, while a denied oncology drug line can take weeks of appeals to recover. Book a demo to see how Pabau checks drug claims for missing details before they reach the payer.

Continue your research

Need a denial resolution framework for drug claims? Denial management in healthcare covers root-cause analysis and appeal strategies for common payer rejections.

Need to decode the reason code on a J0641 denial? Denial codes in medical billing explains common CARC and RARC codes that appear on drug-claim EOBs.

Billing racemic leucovorin instead? HCPCS code J0640 covers leucovorin calcium units, coverage, and documentation.

Want to understand the broader claim lifecycle for Part B drugs? What is revenue cycle management maps the full journey from physician order to payment posting.

Frequently asked questions